Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Account Payables
Amounts the company owes suppliers for goods and services received.
Annovis Bio, Inc.NYSE: ANVS
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 285.0% from a year ago
Account payables stood at $5.28M at the end of Q1 FY2026, up 285.0% from a year earlier and up 103.6% from the prior quarter. Over 3 fiscal years it compounded at -13.2% a year.
Context
- Account payables amounted to 32.5% of total assets at the end of Q1 FY2026, up 27.4 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +285.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.59M USD
- Year-over-year change
- +12.3%
- 4-year CAGR
- +39.3%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.59M | +12.3% |
| FY2024 | 2024-12-31 | 2.31M | +78.4% |
| FY2023 | 2023-12-31 | 1.29M | -67.4% |
| FY2022 | 2022-12-31 | 3.96M | +475.7% |
| FY2021 | 2021-12-31 | 688.07K | — |
Account Payables vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 account payables of $5.28M is the 3rd highest of the 6 companies compared; the peer median is $3.65M.
- Its year-over-year change of +285.0% is the highest of 6, against a peer median of +13.4%.
- Account payables amounts to 32.5% of total assets for ANVS, versus a peer median of 14.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $26.42M | +13.4% | +65.7% | 24.6% | |
| Jun 2026 | $8.51M | +10.4% | — | 21.2% | |
| Mar 2026 | $5.28M | +285.0% | -13.2% | 32.5% | |
| Mar 2026 | $3.65M | +27.7% | +43.1% | 14.8% | |
| Mar 2026 | $2.98M | +62.0% | +20.5% | 8.4% | |
| Mar 2026 | $1.54M | -23.9% | +35.8% | 8.0% | |
| Peer median (excluding ANVS) | $3.65M | +13.4% | +39.4% | 14.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.